Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Immunostaining detects dysplasia in Barrett's and IBD

Alpha-methylacyl-CoA racemase is involved in the neoplastic progression in Barrett's and IBD, and may be useful to detect dysplasia in the epithelia, reports this month's American Journal of Surgical Pathology.

News image

fiogf49gjkf04

Alpha-Methylacyl-CoA racemase catalyzes the racemization of alpha-methyl, branched carboxylic coenzyme A thioesters.

It is overexpressed in a variety of neoplasms, such as prostate and colon cancer.

Dr Russell Dorer and colleagues evaluated alpha-methylacyl-CoA racemase expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's, ulcerative colitis, and Crohn's.

The researchers determined whether its expression can be used to detect dysplastic epithelium in these conditions.

The research team immunostained 134 routinely processed biopsy and/or resection specimens from 134 patients with Barretts.

Immunostainings in 14 specimens were indefinite for dysplasia, 16 were low-grade dysplasia, and 32 were high-grade dysplasia.

The team also immunostained 36 invasive adenocarcinoma, and 74 specimens from 74 patients with inflammatory bowel disease (IBD).

Alpha-methylacyl-CoA racemase was expressed in 81% with high-grade dysplasia
American Journal of Surgical Pathology

The researchers immunostained the specimens with a monoclonal alpha-methylacyl-CoA racemase antibody.

The degree of cytoplasmic staining in all cases was evaluated in a blinded fashion according to a grading system.

In patients with Barrett's, alpha-methylacyl-CoA racemase was not expressed in any negative foci but was increased in foci of low-grade dysplasia by 38%.

The team found that alpha-methylacyl-CoA racemase was expressed in 81% with high-grade dysplasia, and 72% in invasive adenocarcinoma.

The researchers noted that 23% of indefinite for dysplasia foci from 3 Barrett's Esophagus patients were only focally positive.

However, 1 of these 3 patients had follow-up information available, and had developed invasive adenocarcinoma subsequently.

Similarly, in patients with IBD, the team noted that alpha-methylacyl-CoA racemase was not expressed in any foci considered negative for dysplasia.

It was significantly increased in 96% of foci with low-grade dysplasia, 80% with high-grade dysplasia, and 71% with invasive adenocarcinoma.

Only 14% of indefinite for dysplasia focus from 1 patient was focally positive.

The sensitivity for the detection of low-grade dysplasia and high-grade dysplasia in Barrett's and IBD was 38% and 81%, and 96% and 80%, respectively.

The researchers observed that the specificity was 100% for both Barrett's Esophagus and IBD.

Dr Dorer's team concludes, “Alpha-methylacyl-CoA racemase is involved in the neoplastic progression in Barrett's Esophagus and IBD.”

“The high degree of specificity of alpha-methylacyl-CoA racemase for dysplasia/carcinoma in Barrett's Esophagus and IBD suggests that it may be useful to detect neoplastic epithelium in these conditions.”

Am J Surg Path 2006: 30(7): 871-7
12 July 2006

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us